The Human Fertilisation and Embryology Bill was given a Third Reading in the House of Commons on 22 October 2008, by a majority of 355 votes to 129, which means that, following its final stages in the House of Lords, it will be given the Royal Assent and become an Act of Parliament. How long it will prove to be sufficient is another matter.
A look through the verbatim Hansard report on the 3½-hour debate 1 will leave many readers with an uneasy feeling that the UK has indeed embarked on a slippery slope as far as the ethics of human, animal and human-animal experimentation is concerned. As Dr John Pugh MP pointed out, "slopes are a lot more slippery, if we do not examine carefully where we are treading and what exactly we are doing". He also asked "Why should we legislators leave it to scientists to set limits on what is morally permissible?"
One source of confusion was how human-animal admixed embryos should be defined. David Burrowes MP referred to a statement by Lord Darzi in the previous Third Reading debate in the House of Lords, who had said that the Government wanted the forthcoming Act to have a "regulation-making power to extend the definition of human admixed embryos if necessary", "to ensure that if someone comes up with the type of human-animal embryo at the human end of the spectrum that is not captured by the definition, there is a power to extend the definition to catch it." Mr Burrowes rightly commented that this would not be satisfactory, since "it is for this House to try to ensure to the best of our ability that we get the definitions right, so that they are fully comprehensive and so that everyone out there -the scientists and the public -is clear about what we mean."
There was then a lot of discussion about how much human and animal DNA had to be present before an embryo could be considered an admixed embryo, and whether the regulation of its creation and use should be governed by the Home Office via the animaloriented Animals (Scientific Procedures) Act 1986 (ASPA), or by the human-oriented Human Fertilisation and Embryology Authority (HFEA) via the Act which would result from the Bill under discussion. The Government's preference is that 50% or more human DNA would bring the embryo under the purview of the HFEA, but various learned scientists have pointed out it would be difficult to clearly define such a 50% cut-off point. This was one of a number of red herrings which were allowed to creep into the debate, since, however much animal material was present in a cybrid embryo, it would not represent a "protected animal" under the ASPA, if it was created only to be maintained in vitro for up to 14 days. The ASPA would only come into force, if, heaven forbid, it was to be implanted into the uterus of an animal.
This possibility would not be permitted by the new Act, but how long would it be before scientists would want to do just that? Mr Burrowes expressed concern at the evidence given to a Joint Committee in June 2007 by Dr Stephen Minger, Director of the Stem Cell Biology Laboratory at the Wolfson Centre for Age-Related Diseases, King's College London, that scientists would soon want to "take human embryonic stem cells, insert them into a primate blastocyst, and take that blastocyst to mid-gestation, or maybe to birth, or maybe to ten years of age". This led to further confusion -would such a blastocyst be animal, human or admixed?
Dr Evan Harris MP added to the confusion by being under the impression that licences permitting animal experimentation are issued by the Animal Procedures Committee (APC). The APC is an advisory committee. Under the ASPA, Personal Licences and Project Licences are issued by the Home Secretary, acting on the advice of Home Office officials, to permit experimental or other scientific procedures applied to protected animals which may have the effect of causing them pain, suffering, distress or lasting harm.
Mrs Nadine Dorries MP took up the question of seeking to inseminate animals with human sperm, referring to Stalin's attempt to get his top scientist, Ilya Ivanov, to produce the ultimate soldier (who would not be fussy about what he ate, did not feel pain, and would be invincible) by crossing human beings with apes. Stalin clearly didn't know much about apes (or, possibly, human beings either…).
Mrs Dorries' concerns were greeted with ridicule by some MPs, who, presumably, had not appreciated the significance of Dr Minger's comments. Then Kevin Barron MP inadvertently revealed one of the problems underlying British science, when, after pointing out that all MPs had just received a briefing from the Medical Research Council, the Academy of Medical Sciences, the Association of Medical Research Charities, and the Wellcome Trust, he stated that "we have a duty to recognise what the collective voice of the scientific community says…". These organisations may all sing from the same hymn-sheet, but do they truly represent us all?
And so it went on, until, in her summing-up for the Government, the Minister, Dawn Primarolo MP, made the following remarkable statement: "The Government have listened carefully to views about what should be allowed, what should be proscribed and what controls should exist. I believe that we have arrived at the right balance of controlling but not constraining scientific research, with protection from a "Brave New World" scenario in which science overrides ethics, and avoidance of the extremes of scientific process being blocked by red tape, stifled by regulation, or frustrated by a regime that fails to keep pace with social change. We have taken great pains to future-proof the Bill as much as possible and to address intricate dilemmas now, so that clear legislation and regulation may be in place for the future when medical research is not proven. The kaleidoscope of science is coming to a rest. Careful consideration has been given to the Bill in this House and another place, and the new consensus has been captured. If science leads the field and challenges our basic beliefs and ethics -when science throws our views and ethics into flux -legislation brings regulation and stability. The House has struck a new consensus of allowing science to stretch its wings and develop, but constraining it within what the House considers to be ethically acceptable. The US physician, Richard Cabot, said that science and ethics need to shake hands. The Bill brokers that handshake. It represents a good deal for science and society, and I commend it to the House."
Ms Primarolo was supported by the Opposition spokesmen. Mark Simmonds MP (Conservative) said, "The Bill is built on a moral and ethical regulatory framework that will allow Britain to remain at the forefront of scientific and medical innovation while, importantly, still protecting the special status of the embryo". Norman Lamb MP (Liberal Democrat) said: My party's policy is to be pro-science and pro-research, but in favour of an ethical framework for science, subject to proper limits and safeguards. I shall certainly support the Bill on the Third Reading."
Where had they been on 22 October and on 19 May 2008?
There was little discussion on the scientific necessity for creating human-animal hybrid embryos as a means of producing pluripotent human stem cells, since that this would be permitted had already been agreed in the debate on 19 May. 2 However, Mr Burrowes did refer to concern that "the awareness of stem-cell therapy should lead to greater support for, and investment in, adult stem-cell therapy that is producing the treatments that we all want." That leads to one promising and one depressing conclusion.
Promisingly, there are reports, almost weekly, of breakthroughs in the production of pluripotent stem cells (i.e. stem cells with the potential to produce any differentiated cell in the body) from post-embryonic tissues, including adult tissues. The sad news, however, is that the UK is not investing enough into research on adult stem cells, as a result of which we will fall behind in the development of new therapies for many serious diseases, and some of our best scientists will emigrate to work in countries where their work is viewed more favourably. According to a report in The Sunday Times on 26 October 2008 7 , Professor Colin McGuckin, Professor of Regenerative Medicine, Centre for Cord Blood, Institute of Human Genetics, International Centre for Life, University of Newcastle-upon-Tyne, is to leave the UK to work in France, because too much priority is given by British science to embryo experiments over more-ethical alternatives, such as the production of stem cells from umbilical cord blood, which is severely underfunded.
Meanwhile, it has been announced that the MRC and the California Institute for Regenerative Medicine (CIRM) have forged an international collaboration on stem cell research. According to an MRC release, 8 "The agreement was signed on 20 October 2008 by the UK's Minister for Science, Lord Drayson, and the chairman of the governing board of CIRM, Robert N. Klein. The agreement will make it easier for researchers in California and the UK to obtain joint funding to broaden the potential pool of expertise that can be applied toward research in a specific area. It is expected that researchers on both sides of the Atlantic will form teams that will apply jointly for funding. Lord Drayson said: "The UK is a world leader in stem cell science, with its strong research base in stem cells and developmental biology. By forging collaborations with California, we can bring together the best minds across continents to accelerate the search for cures and the development of stem cell-based therapies, for the benefit of people around the world." Sir Leszek Borysiewicz, Chief Executive of the MRC, said: "The CIRM and the MRC share the ambition of devising new treatments for currently incurable diseases, using the promise of stem cell research. The joint effort we are launching will make CIRM researchers key partners of stem cell scientists here in the UK. By working closely together, we have every reason to hope that we will be able to realise the full potential of stem cell research and bring breakthroughs to the clinic more quickly."
A report in The Times 9 mentions £1.75 billion as the sum available to the CIRM-MRC alliance for stem cell science. If that is true, why is the UK investing so little in the production and use of pluripotent adult stem cells, and why is Speaking for the Government, Lord Darzi referred to a number of amendments related to human admixed embryos. He reminded the Lords that: "One motivation for allowing this research to go ahead is the limited availability of human eggs for advancing techniques in cell nuclear replacement, a process used in therapeutic cloning. Scientists are hoping to use as a substitute rabbit or cow eggs, which are abundantly available. There is clearly a wide spectrum of embryos that could be created using human and animal genetic material. The Bill captures the creation, keeping and use of those embryos that are at the human end of the spectrum -in other words, with predominantly human genetic make-up. Research using embryos at the animal end of the spectrum has been undertaken for some time in this country, and regulated by the Home Office under the Animal (Scientific Procedures) Act 1986." Like a number of Members in the Other Place (House of Commons), Lord Darzi was wrong on this last point -the use of mammalian embryos up to halfway through gestation is not regulated by the Animal (Scientific Procedures) Act 1986 (ASPA). Lord Alton proposed a very sensible amendment to a clause which requires that: "A licence cannot authorise keeping or using a human admixed embryo in any circumstances in which regulations prohibit its keeping or use", by adding "or in any circumstances where the purposes of the proposed research can be achieved by any method not entailing the use of human admixed embryos". Speaking in support of his proposal, Lord Alton referred to the forthcoming loss to British science of Professor McGuckin, because: "Our obsession with experiments on human embryos has led to a failure properly to pursue the alternatives. That, in turn, is having a disastrous effect on both our ability to develop life-saving treatments and to develop good science."
Lord Winston, who recorded his interest as a member of the UK Stem Cell Federation, said that the Foundation had not funded any work on embryonic stem cells, and had received no grant applications from Professor McGuckin. He was dismissive of work on stem cells from umbilical cord blood, which, he said "is a different area of science which is still extremely vague, and has largely been rather unsuccessful in helping treatment of patients so far". Lord Patten supported Lord Alton's proposal, saying that: "It is reasonable and proper to ask science to demonstrate that there are no alternatives before using admixed cells in this way." That may be so, but the experience with the application of the ASPA and Directive 86/609/EEC, both of which require that animal experiments should not be conducted if there are relevant and reliable alternative ways of achieving the objectives of the research, could not be said to be encouraging. Scientists have had little difficulty in avoiding that restriction.
And so the debate continued. It tended to stray into a discussion of the pros and cons of embryonic stem cell research, which was not the point -the question was about the creation of admixed embryos as a means of obtaining embryonic stem cells. Lord Tombs recognised this, and said that: "This amendment is about the use of human-animal embryos, and the proposal is that they should not be used if reasonable alternatives are available. The debate has rather turned into a conception of the amendment as an attack on all embryonic research, which plainly it is not." He reminded the House that: "Many believe that the production of animal-human hybrids crosses a moral Rubicon". He also pointed out that: "The morning after the Other Place had voted to allow the creation of animal-human embryos, Mark Henderson, the science correspondent in the Times, who led a vigorous campaign for cloned animal-human embryos, struck a note of sober caution. He wrote that, 'admixed embryos... are not going to lead to immediate medical breakthroughs... any insights they might offer into diseases such as Parkinson's and Alzheimer's are probably years away', but 'they could be used to investigate how diabetes and motor neurone disease progress and to develop and test new drugs'. Those are valuable things. But if Mark Henderson, the enthusiast, is now so cautious, we may conclude that some of the claims made in this House and in another place have been somewhat overstated."
Lord Darzi said that, at best, Lord Alton's amendment was unnecessary, "because of provisions already in the Bill that ensure that research projects can be licensed only if the creation of the human admixed embryo is necessary", which would be a matter for consideration by the HFEA. He added that insisting that the use of human admixed embryos for the purposes of the research should itself be necessary, "would be contrary to the purpose of using human admixed embryos, which is as a means of researching serious diseases while overcoming the problem of the scarcity of human eggs".
Lord Alton said that the amendment "would not prohibit embryonic stem cell research. It would not prohibit the creation of animal-human hybrids", but would require the HFEA "to seek from every licence applicant, and from the licensing authority, an undertaking that, before using admixed embryos, alternatives had been explored". In particular, he said, the HFEA should be required to consider "the use of adult stem cells, and, through them, the creation of induced pluripotent stem cells as a legitimate alternative to the manufacture of human embryos".
Lord Alton pointed out that, in 2005-06, the MRC had made £17.4 million available for work on stem cells, of which 43.6% was spent on adult stem cells and 56.4% -significantly more -on embryonic stem cells. He then refused to withdraw the amendment, which was put to the vote, and his proposal was defeated by 202 votes to 39.
Many other issues were discussed during the course of the debate. For example, an amendment resulting from discussions with the Academy of Medical Sciences now defines a "human admixed embryo" as "any embryo containing human and animal genetic material where the animal material does not predominate". However, it should be noted that Lord Darzi said that there is now "an additional regulation-making power, introduced by Amendment 2, to amend the existing categories in the light of scientific advances; this will not impede future flexibility". The implications of that power in relation to "flexibility" will, no doubt, become clear in due course.
The Human Fertilisation and Embryology Bill now awaits the Royal Assent.
